These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16729320)

  • 1. Hepatitis C vaccines: Inducing and challenging memory T cells.
    Shiina M; Rehermann B
    Hepatology; 2006 Jun; 43(6):1395-8. PubMed ID: 16729320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
    Folgori A; Capone S; Ruggeri L; Meola A; Sporeno E; Ercole BB; Pezzanera M; Tafi R; Arcuri M; Fattori E; Lahm A; Luzzago A; Vitelli A; Colloca S; Cortese R; Nicosia A
    Nat Med; 2006 Feb; 12(2):190-7. PubMed ID: 16462801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection.
    Puig M; Major ME; Mihalik K; Feinstone SM
    Vaccine; 2004 Feb; 22(8):991-1000. PubMed ID: 15161076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
    Zhang S; Bakshi RK; Suneetha PV; Fytili P; Antunes DA; Vieira GF; Jacobs R; Klade CS; Manns MP; Kraft AR; Wedemeyer H; Schlaphoff V; Cornberg M
    J Virol; 2015 Aug; 89(16):8304-17. PubMed ID: 26041301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.
    Jeong SH; Qiao M; Nascimbeni M; Hu Z; Rehermann B; Murthy K; Liang TJ
    J Virol; 2004 Jul; 78(13):6995-7003. PubMed ID: 15194776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation.
    Zubkova I; Choi YH; Chang E; Pirollo K; Uren T; Watanabe H; Wells F; Kachko A; Krawczynski K; Major ME
    Vaccine; 2009 Apr; 27(19):2594-602. PubMed ID: 19428866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immunity and the outcome of hepatitis C virus infection.
    Shoukry NH; Cawthon AG; Walker CM
    Annu Rev Microbiol; 2004; 58():391-424. PubMed ID: 15487943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
    Barth H; Rybczynska J; Patient R; Choi Y; Sapp RK; Baumert TF; Krawczynski K; Liang TJ
    Hepatology; 2011 Oct; 54(4):1135-48. PubMed ID: 21674561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The combined application of nucleotide and amino acid sequences of NS3 hepatitis C virus protein, DNA encoding granulocyte macrophage colony-stimulating factor and inhibitor of regulatory T cells induces effective immune response against hepatitis C virus].
    Masalova OV; Lesnova EI; Shingarova LN; Tunitskaia VL; Ulanova TI; Burkov AN; Kushch AA
    Mol Biol (Mosk); 2012; 46(3):525-34. PubMed ID: 22888642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.
    Martinez-Donato G; Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Pérez A; Dubuisson J; Wychowsk C; Musacchio A; Aguilar D; Dueñas-Carrera S
    Vaccine; 2014 Mar; 32(15):1720-6. PubMed ID: 24486345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
    Forns X; Payette PJ; Ma X; Satterfield W; Eder G; Mushahwar IK; Govindarajan S; Davis HL; Emerson SU; Purcell RH; Bukh J
    Hepatology; 2000 Sep; 32(3):618-25. PubMed ID: 10960458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.